Hypocretin/orexin and sleep: Implications for the pathophysiology and diagnosis of narcolepsy

Current Opinion in Neurology

Volumn 15, Issue 6, 2002, Pages 739-745

  Overeem, Sebastiaan ^a   Scammell, Thomas E ^b   Lammers, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cataplexy; Diagnosis; Hypocretin; Narcolepsy; Obesity; Orexin; Sleep regulation

Indexed keywords

LEPTIN; OREXIN;

AUTONOMIC NERVOUS SYSTEM FUNCTION; CATAPLEXY; CEREBROSPINAL FLUID LEVEL; ENERGY BALANCE; HUMAN; NARCOLEPSY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; SOMNOLENCE; WAKEFULNESS;

ANIMALS; CARRIER PROTEINS; CATAPLEXY; DISEASE MODELS, ANIMAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; PREDICTIVE VALUE OF TESTS; SLEEP; SLEEP STAGES; SLEEP, REM;

EID: 0036907472     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200212000-00013     Document Type: Review

References (67)

1. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95:322-327.
2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92:573-585.
3. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98:365-376.
4. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999; 98:437-451.
5. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355:39-40.
6. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: Clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001; 18:78-105.
7. Sutcliffe JG, de Lecea L. The hypocretins: Setting the arousal threshold. Nat Rev Neurosci 2002; 3:339-349.
8. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001; 24:429-458.
9. Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002; 25:283-313.
10. International Classification of Sleep Disorders: Diagnostic and Coding Manual, Revised. Rochester, Minnesota: American Sleep Disorders Association; 1997.
11. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997; 20:620-629.
12. Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 1993; 43:55-60.
13. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001; 50:381-388. This is the first large study on CSF hypocretin-1 levels after the initial report of hypocretin deficiency in human narcolepsy. Hypocretin-1 was undetectable in 32 out of 38 patients, and body mass increased in many.
14. Tsukamoto H, Ishikawa T, Fujii Y, et al. Undetectable levels of CSF hypocretin-1 (orexin-A) in two prepubertal boys with narcolepsy. Neuropediatrics 2002; 33:51-52.
15. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001; 57:2253-2258. To determine the specificity of low hypocretin-1 for narcolepsy, the authors measured the peptide in a group of 48 controls and 235 patients with various neurological conditions. Hypocretin-1 was detectable in all cases, except for three individuals with Guillain-Barré syndrome, making this the first disease other than narcolepsy with undetectable hypocretin.
16. Kanbayashi T, Yano T, Ishiguro H, et al. Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: Infants to elderly persons. Sleep 2002; 25:1553-1562.
17. Mignot E, Lammers GJ, Ripley B, et al. The role of CSF hypocretin measurements in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59:1553-1562. To establish hypocretin-1 measurements as a diagnostic tool for narcolepsy, the authors analysed hypocretin-1 levels in 274 patients with sleep disorders (e.g. typical and atypical narcolepsy, hypersomnia, sleep apnea, insomnia) and 296 controls. Using quality receiver operator characteristics, hypocretin-1 values with the best diagnostic sensitivity/specificity ratios were determined.
18. Bassetti C, Gugger M, Bischof M, et al. The narcoleptic borderland: A multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med (in press).
19. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002; 11:91-93. This paper, together with [18], reports on hypocretin-1 levels in atypical narcolepsy cases: patients without cataplexy or negative for HLA DQB1*0602. In these atypical patients, hypocretin levels were normal.
20. Guilleminault C, Pelayo R. Narcolepsy in children: A practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000; 2:1-9.
21. Nishino S, Mignot E. Article reviewed: Plasma orexin-A is lower in patients with narcolepsy. Sleep Med 2002; 3:377-378.
22. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6:991-997.
23. Olafsdottir BR, Rye DB, Scammell TE, et al. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 2001; 57:1896-1899.
24. Hungs M, Lin L, Okun M, Mignot E. Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 2001; 57:1893-1895.
25. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27:469-474.
26. Chou TC, Lee CE, Lu J, et al. Orexin (hypocretin) neurons contain dynorphin. J Neurosci 2001; 21:RC168 (1-6).
27. Peyron C, Charnay Y. Hypocretin (orexin) and narcolepsy [abstract]. J Sleep Res 2002; 11:260.
28. Arii J, Kanbayashi T, Tanabe Y, et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001; 56:1775-1776.
29. Scammell TE, Nishino S, Mignot E, Saper CB. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001; 56:1751-1753.
30. Melberg A, Ripley B, Lin L, et al. Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol 2001; 49:136-137.
31. Overeem S, Dalmau J, Bataller L, et al. Secondary narcolepsy in patients with paraneoplastic anti-Ma2 antibodies is associated with hypocretin deficiency [abstract]. J Sleep Res 2002; 11:166-167.
32. Ripley B, Fujiki N, Okura M, et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001; 8:525-534. Detailed study of hypocretin levels in CSF and brain tissue of both sporadic and familial cases of canine narcolepsy, a naturally occurring animal model.
33. Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999; 96:10911-10916.
34. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000; 20:7760-7765.
35. Brown RE, Sergeeva O, Eriksson KS, Haas HL. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 2001; 40:457-459.
36. Bayer L, Eggermann E, Serafin M, et al. Orexins (hypocretins) directly excite tuberomammillary neurons. Eur J Neurosci 2001; 14:1571-1575.
37. Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001; 21:9273-9279.
38. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001; 313:125-128.
39. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 2001; 98:9965-9970.
40. Burlet S, Tyler CJ, Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin/orexin peptides: Implications for wakefulness and narcolepsy. J Neurosci 2002; 22:2862-2872.
41. Estabrooke I, McCarthy MT, Ko E, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001; 21:1656-1662. Fos expression was used to quantify the activity of hypocretin neurons, and was shown to be positively correlated with the amount of wakefulness and negatively correlated with the amount of non-REM and REM sleep.
42. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001; 14:1075-1081. Extracellular hypocretin-1 levels in freely moving rats showed a robust diurnal variation (increasing during the active phase, decreasing during the rest phase). Furthermore, sleep deprivation increased hypocretin release.
43. Kiyashchenko LI, Mireykovskiy BY, Maidment N, et al. Release of hypocretin (orexin) during waking and sleep states. J Neurosci 2002; 22:5282-5286. The authors measured hypocretin-1 levels in microdiarysis samples at 10-min intervals, with simultaneous sleep recordings. Hypocretin levels were highest during active waking and during REM sleep.
44. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 2002; 3:591-605. In-depth review of the neurobiology of sleep: from molecular mechanisms underlying clock function to the interaction of various brain nuclei to generate the sleep cycle.
45. Steriade M, McCarley RW. Brainstem Control of Wakefulness and Sleep. New York: Plenum; 1990.
46. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001; 24:726-731. After reviewing the key nuclei involved in the generation of the different sleep/wake states, the authors describe the important role of the hypothalamus in regulating these systems. A model is proposed, in which wake and sleep-promoting neurons inhibit each other, thereby forming a bistable 'sleep-switch'.
47. Hungs M, Mignot E. Hypocretin/orexin, sleep and narcolepsy. Bioessays 2001; 23:397-408.
48. Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: Implications for sleep and sleep disorders. Trends Neurosci 2000; 23:359-365.
49. Alam MN, Gong H, Alam T, et al. Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area. J Physiol 2002; 538:619-631. In this study the electrical activity of neurons in the lateral hypothalamus during wakefulness and sleep was measured. Several cell populations were found with different patterns of activity during the various vigilance states.
50. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 2000; 355:1274-1275.
51. Dahmen N, Bierbrauer J, Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 2001; 251:85-89. The authors measured the body mass index of 132 narcoleptic patients, and compared the data to a previous survey of self-reported data on body weight and height in the general population.
52. Overeem S, Kok SW, Pijl H, et al. Body weight and composition in patients with narcolepsy versus idiopathic hypersomnia [abstract]. Sleep 2002; 25:A79.
53. Schuld A, Blum WF, Uhr M, et al. Reduced leptin levels in human narcolepsy. Neuroendocrinology 2000; 72:195-198.
54. Kok SW, Meinders AE, Overeem S, et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab 2002; 87:805-809. Detailed study of serum leptin levels in a group of narcoleptics and a group of stringently matched controls, using measurements at 10-min intervals for 24 h.
55. Karsbeek A, Fliers E, Romijn JA, et al. The suprachiasmatic nucleus generates the diurnal changes in plasma leptin levels. Endocrinology 2001; 142:2677-2685.
56. Aston-Jones G, Chen S, Zhu Y, Oshinsky ML. A neural circuit for circadian regulation of arousal. Nat Neurosci 2001; 4:732-738. Using several neuronal tracer techniques, the authors describe an indirect pathway from the biological clock to the locus coeruleus relaying in the hypotharamus.
57. Abrahamson EE, Leak RK, Moore RY. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 2001; 12:435-440.
58. Kok SW, Roelfsema F, Overeem S, et al. Dynamics of the pituitary-adrenal ensemble in hypocretin deficient narcoleptic humans: Blunted basal ACTH release and evidence for normal time-keeping by the master pacemaker. J Clin Endocrinol Metab 2002; 87 (in press).
59. Broughton R, Mullington J. Chronobiological aspects of narcolepsy. Sleep 1994; 17:S35-S44.
60. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997; 52:27-78.
61. Nishino S, Okura M, Mignot E. Narcolepsy: Genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000; 4:57-99.
62. Kisanuki Y, Chemelli RM, Tokita S, et al. Behavioral and polysomnographic characterization of orexin-1 receptor and orexin-2 receptor double knockout mice [abstract]. Sleep 2001; 24:A22.
63. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30:345-354. Description of a new murine model for narcolepsy, in which hypocretin neurons degenerate during the first months of life. These mice develop narcolepsy and lateonset obesity, despite eating less.
64. Lammers GJ, Pijl H, lestra J, et al. Spontaneous food choice in narcolepsy. Sleep 1996; 19:75-76.
65. Beuckmann CT, Hammer RE, Williams SC, et al. A rat model of narcolepsy: genetic ablation of orexin neurons [abstract]. Sleep 2002; 25:A73-A74.
66. Gerashchenko D, Kohls MD, Greco M, et al. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J Neurosci 2001; 21:7273-7283. In this study, hypocretin receptor-expression neurons in the lateral hypothalamus were lesioned using a hypocretin-2-saporin conjugate. This technique shows promise to selectively destroy neurons that receive hypocretin input.
67. van den Pol AN. Narcolepsy: A neurodegenerative disease of the hypocretin system? Neuron 2000; 27:415-418.